People with metabolically healthy obesity may not remain free of metabolic diseases in the long term.

Studies show a link between diabetic peripheral neuropathy and sarcopenia, which increases frailty and subsequent mortality.

Patients with diabetes are two times more likely to present with symptoms of depression; how does this affect diabetes outcomes?

Risk lower for HF, but not major CV events, compared with new users of DPP4 inhibitors

At normal body weight, rates for diabetes three times higher in Hawaiians, Pacific Islanders

Risk for major adverse cardiovascular events reduced with metformin compared with a sulfonylurea

Linagliptin compared with glimepiride for risk for major cardiovascular events in T2DM with elevated CV risk

Findings based on survey of university-affiliated students, staff with either type 1 or type 2 diabetes

Although, for most of us reading this week’s newsletter, the idea of giving a GLP-1 mimetic in a once a week shot presents no problem, there are many patients who could never tolerate even one shot per year. This can present a problem and cause prescribers to choose other medications. …

After starting a new medication (gabapentin) for his neuropathy, a patient of mine gained 30lbs and presented with peripheral edema without symptoms.